FAIRNESS, EQUITY AND EFFICIENCY FOR THE CONVENTION ON BIOLOGICAL DIVERSITY AND THE NAGOYA PROTOCOL: ANALYSIS OF A RODENT, A SNAIL, A SPONGE AND A VIRUS. PART 2

Sociedad Peruana de Derecho Ambiental (SPDA)

Resumen


Case studies based on 4 different organisms to determine the best modality for ABS. We recommend that the Parties reaffirm the nature of the CBD and Nagoya Protocol (NP) as framework agreements. Decisions made at the COP can be revisited and reversed. The adoption of an alternative modality to bilateralism could even include a return to the “Common Heritage of Mankind” (Modality 5), which is just as much an expression of sovereignty as is the bilateral approach. Policy implications must be rendered into recommendations and the recommendations, into legislation. Appendix VI is a “Legal Elements for the ‘Global Multilateral Benefit-sharing Mechanism’ as contemplated in the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization”

Texto completo:

PDF

Referencias


Naked Mole-Rat (Heterocephalus glaber)

- Bens, M., Szafranski, K., Holtze, S., Sahm, A., Groth, M., Kestler, H. A., . . . Platzer, M. (2018). Naked mole-rat transcriptome signatures of socially suppres- sed sexual maturation and links of reproduction to aging. BMC Biol, 16(1), 77. doi:10.1186/s12915-018-0546-z

- Da Silva, C. C., Tomasco, I. H., Hoffmann, F. G., & Lessa, E. P. (2009). Genes and Ecology: Accelerated Rates of Replacement Substitutions in the Cytochrome b Gene of Subterranean Ro- dents. The Open Evolution Journal, 3, 17- 30. doi: 10.2174/1874404400903010017

- Debebe, T., Biagi, E., Soverini, M., Holtze, S., Hildebrandt, T. B., Birkemeyer, C., . . . Birkenmeier, G. (2017). Unraveling the gut microbiome of the long-lived naked mole-rat. Scientific Reports, 7. doi:10.1038/ s41598-017-10287-0

- Debebe, T., Holtze, S., Morhart, M., Hildebrandt, T. B., Rodewald, S., Huse, K., . . . Birkenmeier, G. (2016). Analysis of cultivable microbiota and diet intake pattern of the long-lived naked mole-rat. Gut Pathogens, 8. doi:10.1186/s13099-016-0107-3

- Fang, X. D., Seim, I., Huang, Z. Y., Gerashchenko, M. V., Xiong, Z. Q., Turanov, A. A., . . . Gladyshev, V. N. (2014). Adaptations to a Subterranean Environment and Longevity Revealed by the Analysis of Mole-rat Genomes. Cell Reports, 8(5), 1354-1364. doi:10.1016/j. celrep.2014.07.030

- Hilton, H. G., Rubinstein, N. D., Janki, P., Ireland, A. T., Bernstein, N., Fong, N. L., . . . Buffenstein, R. (2019). Single-cell transcriptomics of the naked mole-rat reveals unexpected features of mammalian im- munity. PLoS Biology, 17(11). doi:10.1371/journal. pbio.3000528

- Honeycutt, R. L. (1992). Naked Mole-Rats. American Scientist, 80(1), 43-53.

- Jarvis, J., U.M., & Sherman, P. W. (2002). Heterocephalus glaber. Mammalian Species(706), 1-9. doi:10.1644/0.706.1

- Jarvis, J. U. M. (1981). Eusociality in a Mammal - Cooperative Breeding in Naked Mole-Rat Colonies. Science, 212(4494), 571-573. doi:10.1126/science.7209555

- Keane, M., Craig, T., Alfoeldi, J., Berlin, A. M., Johnson, J., Seluanov, A., . . . de Magalhaes, J. P. (2014). The Naked Mole-rat Genome Resource: facilitating analyses of cancer and longevity-related adaptations. Bioinformatics, 30(24), 3558-3560. doi:10.1093/ bioinformatics/btu579

- Kim, E. B., Fang, X. D., Fushan, A. A., Huang, Z. Y., Lobanov, A. V., Han, L. J., . . . Gladyshev, V. N. (2011). Genome sequencing reveals insights into physiology and longevity of the naked mole-rat. Nature, 479(7372), 223-227. doi:10.1038/nature10533

- Lagunas-Rangel, F. A., & Chávez-Valencia, V. (2017). Learning of nature: The curious case of the naked mole-rat. Mechanisms of Ageing and Development, 164, 76-81. doi:10.1016/j.mad.2017.04.010

- Law, P. S. o. E. (2017). Lawful Avoidance of ABS: Jurisdiction Shopping and Selection of non-Genetic-Material Media for Transmission. In response to “Proposals for new and emerging issues for SBSTTA-21 and COP-14” (SCBD/ OIC/DC/RH/84326), https://www. cbd.int/doc/emerging-issues/SPDA-submission2017-05-en.pdf, accessed, 25 March 2020.

- MacRae, S. L., Zhang, Q. W., Lemetre, C., Seim, I., Calder, R. B., Hoeijmakers, J., . . . Zhang, Z. D. D. (2015). Comparative analysis of genome maintenance genes in naked mole-rat, mouse, and human. Aging Cell, 14(2), 288-291. doi:10.1111/acel.12314

- Maree, S., & Faulkes, C. (2016). Heterocephalus glaber, The IUCN Red List of Threatened Species 2016: e.T9987A115095455. https://dx.doi.org/10.2305/ IUCN. UK.2016-3.RLTS.T9987A22184136.en, accessed on 25 March 2020.

- Mulatu, G. A. (2018). Overview of African naked mole-rat Heterocephalus glaber for bioprospecting and access and benefit sharing in Ethiopia. GSC Bio- logical and Pharmaceutical Sciences, 04(01), 25-37. doi:10.30574/ gscbps.2018.4.1.0042

- Schuhmacher, L. N., Callejo, G., Srivats, S., & Smith, E. S. (2018). Naked mole-rat acid-sensing ion channel 3 forms nonfunctional homomers, but functional heteromers. Journal of Biological Chemistry, 293(5), 1756-1766. doi:10.1074/jbc.M117.807859

- Schuhmacher, L. N., Husson, Z., & Smith, E. S. J. (2015). The naked mole-rat as an animal model in biomedical research: current perspectives. Open Access Animal Physiology, 7, 137- 148. doi:10.2147/OAAP. S50376

- Seluanov, A., Hine, C., Azpurua, J., Feigenson, M., Bozzella, M., Mao, Z. Y., . . . Gorbunova, V. (2009). Hypersensitivity to contact inhibition provides a clue to cancer resistance of naked mole-rat. Proceedings of the National Academy of Sciences of the United States of America, 106(46), 19352- 19357. doi:10.1073/ pnas.0905252106

- Sherman, P. W., Jarvis, J. U. M., & Alexander, R. D. (1991). Preface. In P. W. Sherman, J. U. M. Jarvis, & R. D. Alexander (Eds.), The Biology of the Naked Mole- Rat (pp. vii-xii). Princeton, New Jersey: Princeton University Press.

- Smith, E. S. J. (2019). Meet the naked mole-rat: impervious to pain and cancer, and lives ten times longer than it should. The Conversation, https://theconversation.com/meet-the-naked-mole-rat-impervious-to- pain-and-cancer-and-lives-ten-times-longer-than-it- should-118809, accessed 25 March 2020.

- Smith, E. S. J., Omerbasic, D., Lechner, S. G., Anirudhan, G., Lapatsina, L., & Lewin, G. R. (2011). The Molecular Basis of Acid Insensitivity in the African Naked Mole- Rat. Science, 334(6062), 1557-1560. doi:10.1126/ science.1213760

- Taye, D. (2017). Identification of African naked mole-rat Heterocephalus glaber for ABS Agreement. CBD Clearing House Mechanism of Ethiopia, http://et.chm- cbd.net/news/ identification-of-african-naked-mole- rat-heterocephalus-glaber-for-abs-agreement accessed 25 March 2020.

- Tian, X., Azpurua, J., Hine, C., Vaidya, A., Myakishev-Rempel, M., Ablaeva, J., . . . Seluanov, A. (2013). High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole-rat. Nature, 499(7458), 346-U122. doi:10.1038/nature12234

- Vogel, J. H., Ruiz Muller, M., Angerer, K., & Oduardo-Sierra, O. (2018). Inside Views: Ending Unauthorised Access To Genetic Resources (aka Biopiracy): Bounded Openness.

- Intellectual Property Watch: https://www.ip-watch. org/2018/04/06/ending-unauthorised-access-geneti cresources-aka-biopiracy-bounded-openness/ Accessed 25 March 2020.

- Wale, M., Kassie, A., & Fekensa, T. (2016). Assessment of naked mole-rat distribution and threats in Eastern Ethiopia. Journal of Coastal Life Medicine, 4(8), 655-658. doi:10.12980/jclm.4.2016J6-95


Cone snails (family Conidae and genus Conus)

- Bagley, M., Karger, E., Perron-Welch, F., de Souza, L. (2020). “Fact-finding study on how domestic measures address benefit-sharing arising from commercial and non- commercial use of digital sequence information on genetic resources and address the use of digital sequence information on genetic resources for research and development”. Technical report of the Ad Hoc Technical Expert Group on Digital Sequence Information on Genetic Resources.

- Broggiato, A., Arnaud-Haond, S., Chiarolla, C., and Greiber, T. (2014), Fair and equitable sharing of benefits from the utilization of marine genetic resources in areas beyond national jurisdiction: Bridging the gaps between science and policy. Marine Policy 49 (novembre): 176-85. https://doi.org/10.1016/j.marpol.2014.02.012.

- Bruce, C., E.C. Fitches, N. Chougule, H.A. Bell, and J.A. Gatehouse. (2011), Recombinant conotoxin, TxVIA, produced in yeast has insecticidal activity. Toxicon 58 (1): 93-100. https://doi.org/10.1016/j.toxicon.2011.05.009.

- Chivian, E., Callum, M.R., and Bernstein, A.S. (2003), The threat to cone snails. Science 302 (5644): 391-391.

- Durek, T. and Craik, D.J. (2015), Therapeutic conotoxins: a US patent literature survey. Expert Opinion on Therapeutic Patents 25 (10): 1159-73. https://doi.org/10.1517/13543776.2015.1054095.

- Dutertre, S. Jin, A., Kaas, Q., Jones, A., Alewood, P.F., and Lewis, R.J. (2013) Deep venomics reveals the mechanism for expanded peptide diversity in cone snail venom. Molecular & cellular proteomics 12 (2): 312-29.

- Dutertre, S. and Lewis, R. (2013) Cone snail biology, bioprospecting and conservation. Emil M. Hämäläinen, Sofia Järvinen. Snails: biology, ecology and conservation, Nova Science Publishers.

- Gao, B., Chao, P., Yang, J., Yi, Y., Zhang, J., and Shi, Q. (2017), Cone snails: A big store of conotoxins for novel drug discovery. Toxins 9 (12): 397.

- Grabowski, K., and Schneider, G. (2007), Properties and Architecture of Drugs and Natural Products Revisited. Current Chemcial Biology, 1, 115-127.

- Grau, V., Richter, K., Hone, A.J., and McIntosh, J.M. (2019) Conopeptides [V11L; V16D] ArIB and RgIA4: powerful tools for the identification of novel nicotinic acetylcholine receptors in monocytes. Frontiers in pharmacology 9: 1499.

- Greer, D.S. Greer, D., Harvey, B., and (2004), Blue genes: sharing and conserving the world’s aquatic biodiversity. Earthscan.

- Harvey, A. (2008), Natural products in drug discovery. Drug Discov Today. 13(19-20):894‐901. doi:10.1016/j. drudis.2008.07.004.

- Harvey, A.L. (2014),Toxins and drug discovery. Toxi- con 92: 193-200.

- Hillyard, D.R., Monje, V.D., Mintz, I.M., Bean, B.P., Nadasdi, L., Ramachandran, J., Miljanich, G., Azimi Zoonooz, A., McIntosh, J.M. and Cruz, L.J. (1992), A new Conus peptide ligand for mammalian presynaptic Ca2+ channels. Neuron 9 (1): 69-77.

- Hu, H., Bandyopadhyay, P.K., Olivera, B.M., and Yandell, M. (2011), Characterization of the Conus bullatus genome and its venom-duct transcriptome. BMC genomics 12 (1): 60.

- Kohn, A.J., Saunders, P.R., and Wiener, S. (1960),Preliminary studies on the venom of the marine snail Co- nus. Annals of the New York Academy of Sciences 90 (3): 706-25.

- Lavergne, V., Dutertre, V., Jin, A., Lewis, R.J., Taft, R.J., and Alewood, P.F. (2013), Systematic interrogation of the Conus marmoreus venom duct transcripto- me with ConoSorter reveals 158 novel conotoxins and 13 new gene superfamilies. BMC genomics 14 (1): 708.

- Liebig, Klaus, Daniel Alker, Karim ould Chih, Dag- mar Horn, Holger Illi, et Julia Wolf. (2002). “ Governing biodiversity: access to genetic resources and approaches to obtaining benefits from their use: the case of the Philippines ”. Working Paper 05/2002. German Development Institut.

- Lobo-Ruiz, Ariadna, et Judit Tulla-Puche. (2018). “ Synthetic approaches of naturally and rationally designed peptides and peptidomimetics ”. In Peptide Appli- cations in Biomedicine, Biotechnology and Bioengineering, 23-49. Elsevier.

- Mansbach, Rachael A, Timothy Travers, Benjamin H McMahon, Jeanne M Fair, and S Gnanakaran. (2019). “ Snails in silico: A review of computational studies on the conopeptides ”. Marine drugs 17 (3): 145.

- McIntosh, M., L.J. Cruz, M.W. Hunkapiller, W.R. Gray, and B.M. Olivera. (1982). “ Isolation and structure of a peptide toxin from the marine snail Conus magus ”. Archives of Biochemistry and Biophysics 218 (1): 329-34. https://doi. org/10.1016/0003-9861(82)90351-4.

- Newman, D.J., Cragg, G.M. (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 75(3):311‐335. doi:10.1021/ np200906s

- Olivera, B.M (2002), Conus venom peptides: reflecions from the biology of clades and species. Annual Review of Ecology and Systematics 33 (1): 25-47.

- Olivera, B.M and Cruz, L.J.(2001), Conotoxins, in retrospect. Toxicon (Oxford) 39 (1): 7-14.

- Olivera, B.M. and Russell, T. (2007), Diversity of the Neurotoxic Conus Peptides: A Model for Concerted Pharmacological Discovery. Molecular interventions 7 (novembre): 251-60. https://doi.org/10.1124/mi.7.5.7

- Peng, C.,Ge, Y., Gao, B.M., Fan, C.X., Bian, C., Wang, J., Cao, Y., Wen, B., Zhu, Y., and Ruan, Z., (2016)High- throughput identification of novel conotoxins from the Chinese tubular cone snail (Conus betulinus) by multi transcriptome sequencing. GigaScience 5 (1): s13742-016.

- Puillandre, N, P Bouchet, TF Duda Jr, S Kauferstein, AJ Kohn, BM Olivera, M Watkins, et C Meyer. (2014). “Molecular phylogeny and evolution of the cone snails (Gastropoda, Conoidea)”. Molecular phylogenetics and evolution 78: 290-303.

- Puillandre, Nicolas, Reto Stöcklin, Philippe Favreau, Estelle Bianchi, Frédéric Perret, Audrey Rivasseau, Loïc Limpalaër, Eric Monnier, et Philippe Bouchet. (2014). “When everything converges: Integrative taxonomy with shell, DNA and venomic data reveals Conus conco, a new species of cone snails (Gastropoda: Conoidea)”. Molecular Phylogenetics and Evolution 80 (novembre): 186-92. https://doi.org/10.1016/j.ympev.2014.06.024

- Röckel, D., Kohn, A.J and Korn, W. (1995), Manual of the living Conidae: Indo-Pacific region. Verlag Christa Hemmen.

- Sharpe, I.A., Gehrmann, J., Loughnan, M.L., Thomas, L., Adams, D.A., et al. (2001) Two new classes of conopeptides inhibit the α1-adrenoceptor and noradrenaline transporter. Nature neuroscience 4 (9): 902-7.

- Smagdi, A. (2005) “National Measures on Access to Genetic Resources and Benefit Sharing-The Case of the Philippines. Law Env’t & Dev. J. 1: 50.

- Uribe, J.,Puillandre, N. and Zardoya, R. (2017). Beyond Conus: Phylogenetic relationships of Conidae based on complete mitochondrial genomes. Molecular Phylogenetics and Evolution 107 (février): 142-51. https://doi.org/10.1016/j. ympev.2016.10.008.

- Wallace, M. (2006) Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain. Expert review of neurotherapeutics 6 (10): 1423-28.

- Wells, W. (1998), The snail companies. Chemistry & Biology 5 (9): R235-36.

- Wynberg, R (2015), Marine genetic resources and bioprospecting in the Western Indian Ocean. Western Indian Ocean, 407


Marine Sponge (Tectitethya crypta)

- Aoki, F. Y. (2015). Antivirals against Herpes viru- ses. In Bennet E., Dolin R. & Blaser M H. (Eds.), Mandell, Douglas and Bennett Principles and Prac- tice of Infectious Diseases (English Edition). ISBN: 13-978-1-4557-4801-3, Elsevier Saunders.

- Bartlett, R. T., Cook, A. F., Holman, M. J., Mc- Comas, W. W., Nowoswait, E. F., Poonian, M. S., ... & Marwood, J. F. (1981). Synthesis and pharmacological evaluation of a series of analogs of 1-methylisoguanosine. Journal of Medicinal Chemistry, 24(8), 947-954.

- Benevolent AI (2020). Peter Richardson (websi- te profile). Available at: https://www.benevolent.com/team/peter-richardson

- Bergmann, W., & Feeney, R. J. (1950). The isolation of a new thymine pentoside from sponges I. Journal of the American Chemical Society, 72(6), 2809-2810.

- Bergmann. W. & Feeney R., (1951) Contributions to the study of marine products. XXXII. The nucleosides of sponges I, The Journal of Organic Chemistry, 16 (6). 981-987. DOI: 10.1021/jo01146a023

- Bergmann, W., & Stempien Jr, M. F. (1957). Contributions to the study of marine products. XLIII. The nucleosides of sponges. V. The synthesis of spongosine1. The Journal of Organic Chemistry, 22(12), 1575-1577.

- Bertin, M. J., Schwartz, S. L., Lee, J., Koro- beynikov, A., Dorrestein, P. C., Gerwick, L., & Gerwick, W. H. (2015). Spongosine production by a Vibrio harveyi strain associated with the sponge Tectitethya crypta. Journal of Natural Pro- ducts, 78(3), 493-499.

- Boyd, M. R., Bacon, T. H., & Sutton, D. A. V. I. D. (1988). Anti Herpesvirus activity of 9-(4-hydroxy-3-hydroxymethyl but-1-yl) guanine (BRL 39123) in animals. Antimicrobial Agents and Chemotherapy, 32(3), 358-363

- Boué-Grabot, E., Blum, D., & Ceruti, S. (Eds.). (2020). Purinergic Signaling in Health and Disease. Frontiers Media SA.

- Bouton, Katherine. (1989). The Nobel Pair. The New York Times. Available online at: https://www.nytimes.com/1989/01/29/magazine/the-nobel-pair.html , accessed on 6 June, 2020

- De Clercq, E., & Li, G. (2016). Approved antiviral drugs over the past 50 years. Clinical Microbiology Reviews, 29(3), 695-747.

- Denny, W.A. (2010). Synthetic DNA-targeted chemotherapeutic agents and related tumour-activated prodrugs. Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand from Burger’s Medicinal Chemistry, Drug, Discovery and Development, Cancer, 5. Edited by Donald J. Abraham & David P. Rotella. John Wiley & Sons, Inc., Canada

- El-Subbagh, H. I., & Al-Badr, A. A. (2009). Cytarabine. In Profiles of Drug Substances, Excipients and Related Methodology (Vol. 34, pp. 37-113). Academic Press.

- GlaxoSmithKline (GSK) (2016). GSK’s global HIV business ViiV Healthcare completes transactions to acquire Bristol-Myers Squibb’s R&D HIV assets. 22 February 2016. Available at: GSK’s global HIV business ViiV Healthcare completes transactions to acquire Bristol-Myers Squibb’s R&D HIV assets | GSK , accessed on March, 2020)

- GSK (2001-2020). Our History. Available at: History and heritage | GSK, accessed on March, 2020

- Gupta, H., Kumar, S., Roy, S. K., & Gaud, R. S. (2010). Patent protection strategies. Journal of Pharmacy and Bioallied Sciences, 2(1), 2.

- Jennings, D. E., DiBattista, J. D., Stump, K. L., Hussey, N. E., Franks, B. R., Grubbs, R. D., & Gruber, S. H. (2012). Assessment of the aquatic biodiversity of a threatened coastal lagoon at Bimini, Bahamas. Journal of Coastal Conservation, 16(3), 405-428.

- Kaschner, K., K. Kesner-Reyes, C. Garilao, J. Segschneider, J. Rius-Barile, T. Rees, and R. Froese. 2019. AquaMaps: Predicted range maps for aquatic species. World Wide Web electronic publication, www.aquamaps.org, version 10/2019.

- Latosińska, J. N., & Latosińska, M. (2013). Anticancer drug discovery from serendipity to rational design. Drug discovery. Poland: InTech, 35-74.

- Laubenfels M.W. de. (1949). Sponges of the western Bahamas. American Museum Novitates. 1431: 1-25. page(s): 20-21

- Lee, W.W. A. Benitez, L. Goodman, B.R. Baker, Potential anticancer agents. XL. Synthesis of the banomer of 9-(d-arabinofuranosyl)-adenine. J. Am. Chem. Soc., 1960; 82: 2648–9

- Lichtman, M. A. (2013). A historical perspective on the development of the cytarabine (7 days) and daunorubicin (3 days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+ 3. Blood Cells, Molecules, and Diseases, 50(2), 119-130.

- Mathe G., Amiel J. L, Schwarzenberg L., Schneider M., Cattan A, Schlumberger J. R, Hayat M., & deVassal F. (1970). Chemotherapy of Acute Lymphoblastic Leukaemia. University of Tokyo Press, p. 679-687 in Progress in Microbial and Anticancer Chemotherapy Volume II, Institute of Cancerology and Immunogenetics, Hosp. Paul-Brousse and service of Hematology of the Institut Gustave-Roussy, France.

- Mayer, A. M., Glaser, K. B., Cuevas, C., Jacobs, R. S., Kem, W., Little, R. D. & Shuster, D. E. (2010). The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends in Pharmacological Sciences, 31(6), 255-265.

- Moore, S., Waldholz, M., Raghavan, A. (2002). Glaxo Wellcome Agrees to Acquire SmithKline Beecham for $75.7 Billion. Wall Street Journal. Available at: https://www.wsj.com/articles/SB948069657140115932, accessed on 31 May 2020

- Newman, D.J.; Cragg, G.M.; Battershill, C.N. (2009) Therapeutic Agents from the Sea: Biodiversity, Chemo-Evolutionary Insight and Advances To the End of Darwin’s 200th Year; National Library of Medicine: Bethesda, MD, USA.

- Newman, D. J., & Cragg, G. M. (2016). Natural products as sources of new drugs from 1981 to 2014. Journal of natural products, 79(3), 629-661.

- Newman, D. J. (2018). “From large-scale collections to the potential use of genomic techniques for the supply of drug candidates”. Frontiers in Marine Science, doi: http://dx.doi.org.ezproxy.otago.ac.nz/10.3389/fmars.2018.00401

- Pfizer. (2020). Pharmacia merger 2003: Pfizer and Pharmacia merger. Available at: Pharmacia Merger | Pfizer. (Accessed on June 06, 2020).

- Pharma Letter (1997). Penciclovir Launched In USA, Penciclovir Launched In USA - Pharmaceutical industry news (thepharmaletter.com). (Accessed on March 30, 2020).

- Powell, J. (2019). Inside Benevolent AI: the $2bn tech company backed by Neil Woodford [Update]. Financial Times. Available at: Inside BenevolentAI: the $2bn tech company backed by Neil Woodford [Update] | Financial Times (ft.com), accessed on January 2021

- Research Excellence Framework (REF) (2014). Cambridge Biotechnology-developing drugs at adenosine and leptin receptors. UoA5. Online PDF available at: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjBxoLqmeT_AhXECtQKHWLKBXoQFnoECAcQAQ&url=https%3A%2F%2Fresults.ref.ac.uk%2F(S(bu4crbqxaqnlbbarbprdlxmo))%2FDownloadFile%2FImpactCaseStudy%2Fpdf%3FcaseStudyId%3D32046&usg=AOvVaw3_6_c8jtpkIqjyaZM06kQh&opi=89978449, Accesed on 15 March 2020

- S&P Capital IQ [a]. (2021). Cambridge Biotechnology Limited. Private company profile. Accesed on February 15, 2021, from S&P Capital IQ database.

- S&P Capital IQ [b]. (2021). BenvolentAI Limited.: Private company profile. Accesed on February 15, 2021, from S&P Capital IQ database.

- Sarà M. (2002). , 1848, Systema Porifera: A Guide to the Classification of Sponges. Edited by John N.A. Hooper and Rob W.M. Van Soest © Kluwer Academic/ Plenum Publishers, New York, 2002

- Schaeffer, H. J., & Thomas, H. J. (1958). Synthesis of potential anticancer agents. XIV. Ribosides of 2, 6-disubstituted purines. Journal of the American Chemical Society, 80(14), 3738-3742.

- Schaeffer, H. J., Gurwara, S., Vince, R., & Bittner, S. (1971). Novel substrate of adenosine deaminase. Journal of Medicinal Chemistry, 14(4), 367-369.

- Schaeffer, H. J. (1982). Acyclovir chemistry and spectrum of activity. The American journal of medicine, 73(1), 4-6.

- Simmons, T. L., Andrianasolo, E., McPhail, K., Flatt, P., & Gerwick, W. H. (2005). Marine natural products as anticancer drugs. Molecular Cancer Therapeutics, 4(2), 333- 342.

- Sneader, W. (2005). Drug Discovery: A History. John Wiley & Sons Ltd.

- Sorkin, Andrew (2002). Pfizer said to buy large drug rival in $60 billion deal. 15 July 2002. The New York Times.

- The Nassau Guardian (2016). 1.9M Project to Protect Bahamas Genetic Material. Available at: https://thenassauguardian.com/2016/06/15/19mproject-to-protect-bahamas-genetic- material/, accessed on 31 May 2020

- UNSCBD (The Access and Benefitt-Sharing Clearing House) (2020). Bahamas. Available at: https://absch.cbd.int/ countries/BS , accessed on 30 May 2020

- Vierros, M., Suttle, C. A., Harden-Davies, H., & Burton, G. (2016). Who owns the ocean? Policy issues surrounding marine genetic resources. Lim- nol. Oceanogr. Bull., 25(2), 29-35.

- ViiV Healthcare (2019). Our HIV medicines. Available at: https://viivhealthcare.com/en-gb/our-medicines/ , accessed on February, 2020

- Vogel, J. H. (2007). Reflecting financial and other incentives of the TMOIFGR: The biodiversity cartel. A moving target: Genetic resources and options for tracking and monitoring their international flows, 47.

- Walwick, E.R., & Main, R.K. Inhibition of DNA Synthesis by Sodium Ions. Country unknown/ Code not available.

- Wang, M., Carver, J. J., Phelan, V. V., Sanchez, L. M., Garg, N., Peng, Y. & Porto, C. (2016). Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking. Nature Biotechnology, 34(8), 828-837.

- World Health Organization (2019). Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization. Licence: CC BY- NC-SA 3.0 IGO

- Wishart D. S., Feunang Y. D., Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I., Liu Y., Maciejewski A., Gale N., Wilson A., Chin L., Cummings R., Le D., Pon A., Knox C., Wilson M (2017) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 2017 Nov 8. doi: 10.1093/nar/gkx1037. Pyrimidine Nucleosides: https://www.drugbank.ca/ categories/DBCAT000610 Zidovudine: https://www.drugbank.ca/drugs/DB00495 Acyclo- vir: https://www.drugbank.ca/drugs/DB00787 Cytarabine: https://www.drugbank.ca/drugs/ DB00987

- Zea, S., Henkel, T.P., and Pawlik, J.R. 2014. The Sponge Guide: a picture guide to Caribbean sponges. 3rd Edition. Available online at www.spongegui-de.org. Accessed on: 2020-06-06


Ebola

- Assoc. for Molecular Pathology V. Myriad Genetics, Inc., 569 U.S. 576 (US Supreme Court June 13, 2013).

- Branswell. (2019, July 19). CDC made a synthetic Ebola virus to test treatments. It worked. STAT.

- CDC. (2019, October 15). “40 Years of Ebola Virus Disease around the World.” Retrieved from Centers for Disease Control and Prevention: https://www.cdc.gov/vhf/ebola/ history/chronology.html

- CDC. (2019, November 15). “Prevention and Vaccine.” Retrieved from Centers for Disease Controls and Prevention: https://www.cdc.gov/vhf/ebola/prevention/index.html

- CDC. (2019, November 5). “Treatment.” Retrieved from Centers for Disease Control and Prevention: https://www.cdc.gov/ vhf/ebola/treatment/index.html

- CDC. (2019, November 5). “What is Ebola Virus Disease?” Retrieved from Centers for Disease Control and Prevention: https://www.cdc.gov/ vhf/ebola/about.html

- Chowell, G., & Nishiura, H. (2014, October 10). “Transmission dynamics and control of Ebola virus disease (EVD): a review.” BMC Medicine, 12, 196.

- Evans, N. G., Hills, K., & Levine, A. C. (2020, January). “How Should the WHO Guide Access and Benefit Sharing During Infectious Disease Outbreaks?” AMA Journal of Ethics, 22(1), E28-35.

- Freudenthal, E. (2019, June 14). “A short history of an Ebola vaccine.” The New Humanitarian.

- Gaudinski, M. R., Coates, E. E., Novik, L., Widge, A., Houser, K. V., Burch, E. Arnold, F. (2019). “Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 tar-geting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.” Lancet, 889-898.

- Groseth, A., Ströher, U., Theriault, S., & Feldmann, H. (2002). “Molecular characterization of an isolate from the 1989/90 epizootic of Ebola virus Reston among macaques imported into the United States.” Virus Research, 87(2), 155-163.

- Hammond, E. (2019). “Ebola: Company avoids benefit-sharing obligation by using sequences.” Penang: Third World Network.

- Kolar, E. (2014, December 15). “The Ebola Outbreak and Biological Patents.” Retrieved from Hopkins Biotech Network: https://hopkinsbio.org/biotechnology/ebola-outbreak-biological-patents/

- Laupland, K. B., & Valiquette, L. (2014, May/ June). “Ebola Virus Disease.” Canadian Journal of Infectious Diseases and Medical Microbiology, 25(3), 128-129.

- Maxmen, A. (2019, August 12). “Two Ebola drugs show promise amid ongoing outbreak.” Nature.

- McKenna, M. (2019, March 3). “Colonialists Are Coming For Blood – Literally.” WIRED.

- NCBI. (2018, November 7). “National Center for Biotechnology Information.” Retrieved from Ebolavirus: 6 complete genomes: https://www.ncbi.nlm.nih.gov/genomes/GenomesGroup.cgi?taxid=186536

- Pardo, J. P., Shukla, A. M., Chamarthi, G. M., & Gupte, A. M. (2020, May 22). “The journey of remdesivir: from Ebola to COVID-19.” Drugs in Context (9), 4-14.

- Sabue Mulangu, M. L. (2019). “A Randomized, Controlled Trial of Ebola Virus Disease Thera- peutics.” The New England Journal of Medicine, 381, 2293-2303.

- Sanchez, A., & Rollin, P. E. (2005, October). “Complete genome sequence of an Ebola virus (Sudan species) responsible for a 2000 outbreak of human disease in Uganda.” Virus Research, 113(1), 16-25.

- Servick, K. (2014, August 13). “What does Ebola actually do?” Science.

- Towner, J. S., Sealy, T. K., Khristova, M. L., Albariño, C. G., Conlan, S., Reeder, S. A. C. (2008, November). “Newly Discovered Ebola Virus Associated with Hemorrhagic Fever Outbreak in Uganda.” PLoS Pathogens, 4(11).

- US National Library of Medicine. (2018). R3470-3471- 3479 (REGN-EB3) “Expanded Access Protocol (EAP) for Treatment of Ebola Virus.” Tarrytown: Regeneron Pharmaceuticals.

- Volchkov, V. E., Volchkova, V. A., Slenczka, W., Klenk, H. D., & Feldmann, H. (1998, May 25). “Release of Viral Glycoproteins during Ebola Virus Infection.” Virology, 245(1), 110-119.

- Volchkov, V. E., Volchkova, V.A., Eckle, C., Klenk, H., Bouloy, M., LeGuenno, B., Feldmann, H. (1997, March 4). “Emergence of Subtype Zaire Ebola Virus in Gabon.” Virology, 232(1) 139-144

- WHO. (2020, February 10). “Fact Sheet: Ebola Virus Disease.” Retrieved from World Health Organization: https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease

- WHO. (2020, June 1). “Newsroom New Ebola outbreak detected in northwest Democratic Republic of the Congo; WHO surge team supporting the response.” Re- trieved from World Health Organization: https://www.who.int/news/item/01-06-2020-new-ebola-outbreak-detected-in-northwest-democratic-republic-of-the-congo-who-surge-team-supporting-the-response

- WHO. (2021, February 18). “Disease outbreak news: Ebola virus disease – Guinea (17 February 2021).” Retrieved from Relief Web: https://reliefweb.int/report/guinea/disease-outbreak-news-ebola-virus-disease-guinea-17-february-2021




DOI: http://dx.doi.org/10.21503/lex.v21i31.2483

Enlaces refback

  • No hay ningún enlace refback.


Bookmark and Share


Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional.

ISSN:  2313-1861

Acceso al número de visitas y accesos de la revista Estadística.

Licencia Creative Commons